Boehringer Ingelheim International Gmbh

David James Lamb

Georg Dahmann

Matthias Hoffmann

Edward Walker

John Scott

Jasna Klicic

Clive Mccarthy

Spencer Charles R Napier

Jennifer L Swantek Fitzgerald

Karen Parrish

Horst Dollinger

Andreas Schnapp

Dennis Fiegen

Christian Gnamm

Jasna Klicic Badoux

Spencer Napier

The invention relates to new substituted heteroaryls of formula 1 wherein

Heteroaryl SYK inhibitors

The invention relates to new substituted heteroaryls of formula (1), wherein A is selected from the group consisting of N and CH, D is CH, E is selected from the group consisting of C and N, T is C, G is selected from the group consisting of C and N, and wherein each of the broken (dotted) double bonds in ring 1 are selected from either a single bond or a double bond under the proviso that all single and double bonds of ring 1 are arranged in such a way that they all form together with ring 2 an aromatic ring system, and wherein R, M and Rare defined according to claim, and to the above compounds for the treatment of a disease selected from the group consisting of asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis. 

Heteroaryl Syk inhibitors

The invention relates to new amino-indole-substituted imidazolyl-pyrimidines of formula 1 whereinR, R, R, Rand Rare defined as in claimand pharmaceutically acceptable salts thereof and the use of these compounds for the preparation of a medicament for treating a disease selected from asthma, COPD, rheumatoid arthritis, specific lymphomas and specific diseases of the nervous system.

Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments

Growing community of inventors

Mittelbiberach, Germany

David James Lamb